Foundation Medicine (FMI) 18.91 $FMI
New Data from Foundation Medicine and Collaborators Supports Use of Comprehensive Genomic Profiling to Inform Therapeutic Choices in Advanced Breast Cancer
BusinessWire - Mon Jun 06, 1:00PM CDT
--Biomarkers of Immune Checkpoint Inhibitors Identify Opportunity for Clinical Response to Immunotherapies
FMI: 18.91 (-1.17)
Data From a Study Utilizing FoundationOne(R) Heme Indicates Age-Associated Genomic Profiles in Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
--Data Presented by Foundation Medicine and Collaborators at the 2016 ASCO Annual Meeting Further Propels the Advancement of Precision Medicine in Pediatric Cancers
FMI: 18.91 (-1.17)
Foundation Medicine Presents New Data at ASCO 2016 Demonstrating that FoundationOne(R) May Help Predict Response to Cancer Immunotherapy Across a Variety of Advanced Cancers
BusinessWire - Sun Jun 05, 10:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and it collaborators presented data showing that higher tumor mutational burden, as estimated by comprehensive genomic profiling with FoundationOne(R), successfully predicted a greater likelihood of response and longer response duration to cancer immunotherapies in patients with advanced bladder cancer and metastatic melanoma as well as several other tumor types. The results were presented in two oral sessions, and several poster discussions at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
FMI: 18.91 (-1.17)
FoundationOne(R) Identifies Patients with Advanced Lung Cancer Likely to Respond or Develop Resistance to Certain RET Inhibitor Therapies
BusinessWire - Sat Jun 04, 8:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new critical genomics data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 demonstrating the clinical significance of comprehensive genomic profiling (CGP) with FoundationOne(R) in identifying patients with advanced lung cancer most likely to respond to RET inhibitor targeted therapies and also to predict those patients likely to develop resistance to targeted therapy.
FMI: 18.91 (-1.17)
Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay
BusinessWire - Sat Jun 04, 7:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development program. The companion diagnostic will enable physicians to identify those patients most likely to benefit from AstraZeneca's first-in-class poly ADP-ribose polymerase (PARP) inhibitor.
FMI: 18.91 (-1.17)
Foundation Medicine to Present at the Goldman Sachs Annual Healthcare Conference
BusinessWire - Wed Jun 01, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the Goldman Sachs Annual Healthcare Conference on Wednesday, June 8, 2016, at 2:00 p.m. PT in Rancho Palos Verdes, California.
FMI: 18.91 (-1.17)
COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine, Inc., HealthScape Advisors and Novartis as Strategic Investors
Marketwire Canada - Tue May 24, 8:01AM CDT
Leading Health Care Informatics Company Gains Mission Momentum Across Health Care Discovery, Development, Delivery and Payment Sectors
FMI: 18.91 (-1.17), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Foundation Medicine Announces Presentations at ASCO
BusinessWire - Wed May 18, 4:20PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 taking place June 3-7 in Chicago.
FMI: 18.91 (-1.17)
Foundation Medicine Receives Patent Covering Fundamental Methods in Comprehensive Genomic Analysis in Cancer
BusinessWire - Tue May 17, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Patent and Trademark Office has issued U.S. patent number 9,340,830, entitled, "Optimization of Multigene Analysis of Tumor Samples." The patent, which is assigned to Foundation Medicine, includes fundamental claims describing methods of analyzing a cancer patient's tissue or blood specimen to detect multiple classes of genomic alterations. The patent carries a term extending to 2032. The company is also pursuing patent applications covering aspects of its genomic analysis platform with the European Patent Office and in other jurisdictions outside the United States.
FMI: 18.91 (-1.17)
Foundation Medicine reports 1Q loss
Automated Insights - Tue May 03, 4:15PM CDT
CAMBRIDGE, Mass. (AP) _ Foundation Medicine Inc. (FMI) on Tuesday reported a loss of $17.3 million in its first quarter.
FMI: 18.91 (-1.17)
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights
BusinessWire - Tue May 03, 3:04PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2016. Highlights for the quarter included:
FMI: 18.91 (-1.17)
Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay, FoundationACT(TM)
BusinessWire - Tue May 03, 3:02PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of FoundationACT (Assay for Circulating Tumor DNA), an analytically validated and accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. By analyzing circulating tumor DNA isolated from a patient's blood, FoundationACT can identify clinically relevant genomic alterations, and like Foundation Medicine's tissue-based genomic profiles, FoundationOne(R) and FoundationOne Heme(R), FoundationACT delivers this comprehensive molecular information in a concise report that matches the findings with potentially relevant targeted therapies and clinical trials.
FMI: 18.91 (-1.17)
Foundation Medicine and AstraZeneca Collaborate to Develop Companion Diagnostic Assays in Oncology
BusinessWire - Tue May 03, 3:00PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within AstraZeneca's oncology pipeline.
FMI: 18.91 (-1.17)
Foundation Medicine to Present at Upcoming Investor Conferences
BusinessWire - Thu Apr 28, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
FMI: 18.91 (-1.17)
Foundation Medicine's Molecular Information Supports Discovery of Precision Therapeutics for Pediatric Cancers
BusinessWire - Mon Apr 18, 3:30PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today presented new data from more than 1,200 pediatric tumors across 51 cancer subtypes that were analyzed using the company's comprehensive genomic profiling assays, FoundationOne(R) and FoundationOne(R) Heme. The dataset reveals novel and potentially targetable genomic alterations identified during pediatric cancer clinical care that offer the possibility for new research towards novel therapeutics. In a separate but related announcement at the White House Precision Medicine Initiative Summit in February, Foundation Medicine made this data set publically available for research to motivate and accelerate development of new therapies to fight pediatric cancer.
FMI: 18.91 (-1.17)
How Risky Is Myriad Genetics Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Apr 12, 7:22AM CDT
Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be applicable to Myriad Genetics . Shares of the molecular diagnostics testing company took a...
MYGN: 30.95 (-3.07), FMI: 18.91 (-1.17), ILMN: 141.62 (-1.80), GHDX: 26.18 (-0.02)
Foundation Medicine Announces Timing for First Quarter 2016 Financial Results and Conference Call
BusinessWire - Thu Apr 07, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2016, will be released on Tuesday, May 3, 2016. The management team will host a conference call discussing the company's financial results and recent developments on Tuesday, May 3, 2016, at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 85678817.
FMI: 18.91 (-1.17)
New Data with FoundationOne(R) Supports Clinical Utility and Improved Outcomes from Molecularly Matching Non-Small Cell Lung Cancer Patients to Targeted Therapy
BusinessWire - Thu Mar 24, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the publication of two manuscripts that underscore the importance of integrating comprehensive genomic profiling with FoundationOne(R) into the management of patients with advanced lung cancer. Data from these studies demonstrate that comprehensive genomic profiling enabled identification of cancer-driving alterations that were or would have been missed by narrow, more limited hotspot testing. In both studies, researchers concluded that the discordant findings of the testing approaches underscore the fact that comprehensive genomic profiling consistently provides non-small cell lung cancer patients with more accurate and a broader range of treatment options, including clinical trials, versus narrow hotspot tests.
FMI: 18.91 (-1.17)
Foundation Medicine and Memorial Sloan Kettering Publish Validation Data for FoundationOne(R) Heme in the Journal Blood
BusinessWire - Wed Mar 23, 4:00PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and Memorial Sloan Kettering Cancer Center (MSK) today announced the publication of new, seminal data validating FoundationOne(R) Heme - the fully informative comprehensive genomic profiling assay for hematologic malignancies developed as part of their collaboration - further supporting its integration into oncology clinical practice. The data, available online as a first edition and soon to be published in an upcoming issue of the journal Blood, demonstrate that FoundationOne Heme has proven highly accurate in detecting the types of genomic alterations known to impact diagnosis, therapy selection and prognosis in hematologic cancers. Importantly, the publication demonstrates the molecular information gleaned from comprehensive genomic profiling can be utilized to accurately match patients with an appropriate therapeutic approach.
FMI: 18.91 (-1.17)
New Data from Foundation Medicine and Collaborators Supports Use of Comprehensive Genomic Profiling to Inform Therapeutic Choices in Advanced Breast Cancer
BusinessWire - Mon Jun 06, 1:00PM CDT
--Biomarkers of Immune Checkpoint Inhibitors Identify Opportunity for Clinical Response to Immunotherapies
FMI: 18.91 (-1.17)
Data From a Study Utilizing FoundationOne(R) Heme Indicates Age-Associated Genomic Profiles in Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
--Data Presented by Foundation Medicine and Collaborators at the 2016 ASCO Annual Meeting Further Propels the Advancement of Precision Medicine in Pediatric Cancers
FMI: 18.91 (-1.17)
Foundation Medicine Presents New Data at ASCO 2016 Demonstrating that FoundationOne(R) May Help Predict Response to Cancer Immunotherapy Across a Variety of Advanced Cancers
BusinessWire - Sun Jun 05, 10:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and it collaborators presented data showing that higher tumor mutational burden, as estimated by comprehensive genomic profiling with FoundationOne(R), successfully predicted a greater likelihood of response and longer response duration to cancer immunotherapies in patients with advanced bladder cancer and metastatic melanoma as well as several other tumor types. The results were presented in two oral sessions, and several poster discussions at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
FMI: 18.91 (-1.17)
FoundationOne(R) Identifies Patients with Advanced Lung Cancer Likely to Respond or Develop Resistance to Certain RET Inhibitor Therapies
BusinessWire - Sat Jun 04, 8:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new critical genomics data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 demonstrating the clinical significance of comprehensive genomic profiling (CGP) with FoundationOne(R) in identifying patients with advanced lung cancer most likely to respond to RET inhibitor targeted therapies and also to predict those patients likely to develop resistance to targeted therapy.
FMI: 18.91 (-1.17)
Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay
BusinessWire - Sat Jun 04, 7:00AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development program. The companion diagnostic will enable physicians to identify those patients most likely to benefit from AstraZeneca's first-in-class poly ADP-ribose polymerase (PARP) inhibitor.
FMI: 18.91 (-1.17)
Foundation Medicine to Present at the Goldman Sachs Annual Healthcare Conference
BusinessWire - Wed Jun 01, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the Goldman Sachs Annual Healthcare Conference on Wednesday, June 8, 2016, at 2:00 p.m. PT in Rancho Palos Verdes, California.
FMI: 18.91 (-1.17)
COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine, Inc., HealthScape Advisors and Novartis as Strategic Investors
Marketwire Canada - Tue May 24, 8:01AM CDT
Leading Health Care Informatics Company Gains Mission Momentum Across Health Care Discovery, Development, Delivery and Payment Sectors
FMI: 18.91 (-1.17), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Foundation Medicine Announces Presentations at ASCO
BusinessWire - Wed May 18, 4:20PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 taking place June 3-7 in Chicago.
FMI: 18.91 (-1.17)
Foundation Medicine Receives Patent Covering Fundamental Methods in Comprehensive Genomic Analysis in Cancer
BusinessWire - Tue May 17, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Patent and Trademark Office has issued U.S. patent number 9,340,830, entitled, "Optimization of Multigene Analysis of Tumor Samples." The patent, which is assigned to Foundation Medicine, includes fundamental claims describing methods of analyzing a cancer patient's tissue or blood specimen to detect multiple classes of genomic alterations. The patent carries a term extending to 2032. The company is also pursuing patent applications covering aspects of its genomic analysis platform with the European Patent Office and in other jurisdictions outside the United States.
FMI: 18.91 (-1.17)
Foundation Medicine reports 1Q loss
Automated Insights - Tue May 03, 4:15PM CDT
CAMBRIDGE, Mass. (AP) _ Foundation Medicine Inc. (FMI) on Tuesday reported a loss of $17.3 million in its first quarter.
FMI: 18.91 (-1.17)
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights
BusinessWire - Tue May 03, 3:04PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2016. Highlights for the quarter included:
FMI: 18.91 (-1.17)
Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay, FoundationACT(TM)
BusinessWire - Tue May 03, 3:02PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of FoundationACT (Assay for Circulating Tumor DNA), an analytically validated and accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. By analyzing circulating tumor DNA isolated from a patient's blood, FoundationACT can identify clinically relevant genomic alterations, and like Foundation Medicine's tissue-based genomic profiles, FoundationOne(R) and FoundationOne Heme(R), FoundationACT delivers this comprehensive molecular information in a concise report that matches the findings with potentially relevant targeted therapies and clinical trials.
FMI: 18.91 (-1.17)
Foundation Medicine and AstraZeneca Collaborate to Develop Companion Diagnostic Assays in Oncology
BusinessWire - Tue May 03, 3:00PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within AstraZeneca's oncology pipeline.
FMI: 18.91 (-1.17)
Foundation Medicine to Present at Upcoming Investor Conferences
BusinessWire - Thu Apr 28, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
FMI: 18.91 (-1.17)
Foundation Medicine's Molecular Information Supports Discovery of Precision Therapeutics for Pediatric Cancers
BusinessWire - Mon Apr 18, 3:30PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today presented new data from more than 1,200 pediatric tumors across 51 cancer subtypes that were analyzed using the company's comprehensive genomic profiling assays, FoundationOne(R) and FoundationOne(R) Heme. The dataset reveals novel and potentially targetable genomic alterations identified during pediatric cancer clinical care that offer the possibility for new research towards novel therapeutics. In a separate but related announcement at the White House Precision Medicine Initiative Summit in February, Foundation Medicine made this data set publically available for research to motivate and accelerate development of new therapies to fight pediatric cancer.
FMI: 18.91 (-1.17)
How Risky Is Myriad Genetics Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Apr 12, 7:22AM CDT
Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be applicable to Myriad Genetics . Shares of the molecular diagnostics testing company took a...
MYGN: 30.95 (-3.07), FMI: 18.91 (-1.17), ILMN: 141.62 (-1.80), GHDX: 26.18 (-0.02)
Foundation Medicine Announces Timing for First Quarter 2016 Financial Results and Conference Call
BusinessWire - Thu Apr 07, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2016, will be released on Tuesday, May 3, 2016. The management team will host a conference call discussing the company's financial results and recent developments on Tuesday, May 3, 2016, at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 85678817.
FMI: 18.91 (-1.17)
New Data with FoundationOne(R) Supports Clinical Utility and Improved Outcomes from Molecularly Matching Non-Small Cell Lung Cancer Patients to Targeted Therapy
BusinessWire - Thu Mar 24, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the publication of two manuscripts that underscore the importance of integrating comprehensive genomic profiling with FoundationOne(R) into the management of patients with advanced lung cancer. Data from these studies demonstrate that comprehensive genomic profiling enabled identification of cancer-driving alterations that were or would have been missed by narrow, more limited hotspot testing. In both studies, researchers concluded that the discordant findings of the testing approaches underscore the fact that comprehensive genomic profiling consistently provides non-small cell lung cancer patients with more accurate and a broader range of treatment options, including clinical trials, versus narrow hotspot tests.
FMI: 18.91 (-1.17)
Foundation Medicine and Memorial Sloan Kettering Publish Validation Data for FoundationOne(R) Heme in the Journal Blood
BusinessWire - Wed Mar 23, 4:00PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) and Memorial Sloan Kettering Cancer Center (MSK) today announced the publication of new, seminal data validating FoundationOne(R) Heme - the fully informative comprehensive genomic profiling assay for hematologic malignancies developed as part of their collaboration - further supporting its integration into oncology clinical practice. The data, available online as a first edition and soon to be published in an upcoming issue of the journal Blood, demonstrate that FoundationOne Heme has proven highly accurate in detecting the types of genomic alterations known to impact diagnosis, therapy selection and prognosis in hematologic cancers. Importantly, the publication demonstrates the molecular information gleaned from comprehensive genomic profiling can be utilized to accurately match patients with an appropriate therapeutic approach.
FMI: 18.91 (-1.17)
